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Summary
Objective
With the discovery that familial phaeochromocytoma and paraganglioma syndrome can be caused by mutations in each subunit of the Succinate dehydrogenase enzyme (SDH), has come the recognition that mutations in the individual subunits have their own distinct natural histories. Increased genetic screening is leading to the identification of increasing numbers of, mostly asymptomatic, gene mutation carriers and the implementation of screening strategies for these individuals. Yet there is, to date, no international consensus regarding screening strategies for asymptomatic carriers.
Design
A comprehensive pubmed search from 1/1/2000- 28/2/2018 was undertaken using multiple search terms and subsequently a manual review of references in identified papers to identify all clinically relevant cases and cohorts. In this review, the accumulated, published experience of phenotype and malignancy risks of individual SDH subunits is analysed.  Where possible screening results for asymptomatic SDH mutation carriers have been analysed separately to define the penetrance in asymptomatic carriers (asymptomatic penetrance).
Results
The combined data confirms that “asymptomatic penetrance” is highest for SDHD and when there is penetrance, the most likely site to develop a PGL is head and neck (SDHD) and extra-adrenal abdominal (SDHB). However, the risk in SDHB carriers of developing HNPGL is also high (35.5%) and a PCC is low (15.1%), and in SDHD carriers there is a high risk of developing a PCC (35.8%) or abdominal PGL (9.4%) and a small, but significant risk at other sympathetic sites. The data suggest that the risk of malignant transformation is the same for both PCC and extra-adrenal abdominal PGLs (30-35%) in SDHB carriers. In SDHD carriers the risk of malignant transformation was highest in HNPGLs (7.5%), and similar for sympathetic sites (3.8-5.2%).
Conclusions
Using this data we suggest surveillance screening of asymptomatic carriers can be tailored to the underlying SDH subunit and review possible surveillance programmes.


Introduction

Mutations in the genes that encode the subunits of the Succinate dehydrogenase (SDH) enzyme were first associated with familial phaeochromocytoma and paraganglioma (PPGL) predisposition in 2000  ADDIN EN.CITE (1-3). Initially, mutations in SDHD were described, closely followed by mutations in SDHC  ADDIN EN.CITE (4), and SDHB  ADDIN EN.CITE (5). More recently, germline mutations in SDHA  ADDIN EN.CITE (6) and the flavoprotein SDHAF2  ADDIN EN.CITE (7) have also been associated with familial PPGL disease.

With more widespread access to genetic testing, an increasing number of apparently sporadic PPGLs are now being identified as familial (current estimates suggest 40-50%  ADDIN EN.CITE (8-10)). Cascade genetic screening of relatives is, in turn, leading to the identification of increasing numbers of gene mutation carriers, the vast majority of whom are asymptomatic. These genetic advances open up the potential for direct clinical benefit in as many as half of people destined to develop PPGL disease. To realize this benefit, it will be necessary to formulate screening programmes that identify PPGL at an early stage, prior to the development of symptoms and/or metastatic spread. However, there is no international consensus regarding screening strategies for asymptomatic carriers. Important barriers to the development of consensus guidelines for screening include uncertainties, for each subunit, regarding the site, rate of growth and potential for metastasis of PPGL; and (particularly for SDHB) a growing realization, as more asymptomatic carriers are identified, that previous prevalence estimates were erroneously high. Together with the resource/health economic considerations that arise from intensive radiological screening programmes for increasing numbers of often asymptomatic individuals, these issues have led to markedly different strategies being employed between centres, both nationally and internationally.

Recent guidelines  ADDIN EN.CITE (11) combine evidence and expert opinion to direct the appropriate course of management in the ongoing care and monitoring for recurrence or metastatic disease of patients with PPGL disease, and have produced workable algorithms to identify the most likely underlying causative gene in the index case. For many clinicians, however, it is defining the modality and frequency of imaging for the gene carriers identified via cascade screening that is, paradoxically, more difficult. 

It has required more than a decade of accumulated clinical experience and follow-up of SDH-related PPGL to provide sufficient understanding of the natural history to now allow workable guidelines and algorithms to be formulated. Mutations in each different SDH subunit are surprisingly different in terms of inheritance, penetrance, tumour location and risk of malignant transformation. Consequently, there is also a growing recognition that previous screening strategies may now be inappropriate. In parallel with an increased understanding of the genetic basis of familial PPGL disease, there have been significant advances in the diagnostic imaging techniques for the localization of primary and metastatic disease. As the estimates of penetrance and risk of metastatic spread are revised down, it is the balance of the benefits of radiological surveillance, and the consequences for patient anxiety, resource allocation and (where utilized) the effects of ionising radiation on tumour formation (12) that has become the clinical focus of discussion. The clinical use of biomarkers for screening is an exciting prospect for the future.

Most centres have implemented screening strategies for SDH mutation carriers independent of the subunit affected, but it would seem reasonable, with our current cumulative knowledge, to consider starting to define more sub-unit focused strategies.

In this review, we have analysed all the data in the literature on phenotype and malignancy risks of individual SDH subunits in addition to the accumulated, published experience of screening asymptomatic SDH mutation carriers in order to inform the development of screening protocols. Using this data we suggest surveillance screening of asymptomatic carriers can be tailored to the underlying SDH subunit. We describe the issues relating to modality, frequency and age of commencing screening that have, to date, limited the formation of a consensus with regards to the development of screening programmes.

Surveillance programmes

Once an SDH mutation carrier has been identified, it is universally accepted that inclusion in a screening programme is appropriate and that such a programme should include a comprehensive clinical evaluation with biochemical testing for abnormal catecholamine production (plasma and/or urine metanephrines). However, a significant proportion of SDH-associated PPGLs remain clinically and biochemically silent for a prolonged period due to lower tumoural production of catecholamines  ADDIN EN.CITE (13-15), and the majority of parasympathetic PGLs are non-secretory (16). In rece nt years there has been increasing evidence that size of tumour correlates with malignant potential  ADDIN EN.CITE (14, 17, 18), and the aim of screening is to identify tumours at early stages. If novel, more sensitive and specific biomarkers are discovered, we recognise that the role of imaging will diminish. However, it seems clear for now, that imaging must play the central role in screening asymptomatic SDH gene carriers

A number of studies and guidelines have suggested potential surveillance programmes for managing SDH gene mutation carriers, reviewed in detail elsewhere (supplementary table 1) (19). Most of these, however, do not differentiate between the follow-up of asymptomatic carriers and those that have (or have previously had) tumours; and very few suggest ‘tailor made’ surveillance imaging programmes based on specific SDH subunit gene mutations. 

In order to develop a ‘bespoke’ surveillance strategy for SDH mutation carriers, it is first necessary to understand and catalogue differences in the natural history of diseases associated with mutations in the different SDH subunits. As an initial step, we have combined informative data from multiple published cohorts in order to guide the development of potential surveillance protocols for individual SDH subunits. There are inherent difficulties associated with gathering and reporting clinical outcomes in cohorts of SDH mutation carriers and, by implication, limitations to how confidently conclusions can be drawn from attempts to draw together data derived from different centres. We also acknowledge that there is the possibility of overlap in the clinical cohorts analysed (e.g. with groups reporting outcomes on growing cohorts of patients), which we have tried to minimize. 

We present the combined data for each subunit in order of the most commonly identified subunit mutations; recognizing that patients affected by mutations in SDHB and SDHD make up the majority of individuals in most centres. 

SDHB

Penetrance
Mutations in the SDHB gene account for 10% of cases of all PPGLs and approximately one quarter of familial disease  ADDIN EN.CITE (8, 20, 21). To date, a total of 287 unique mutation variants have been reported in the SDH database (22). The importance of surveillance screening in asymptomatic relatives is highlighted when analysing studies that separate out the asymptomatic carriers/relatives from the index cases (Table 1). These combined cohorts provide data on 1341 asymptomatic SDHB carriers and demonstrate a tumour detection rate of 15.4% (207 asymptomatic carriers with PPGLs identified on screening), when index cases are excluded (individual studies report a tumour detection rate ranging from 3.5-35%)  ADDIN EN.CITE (23-34). Penetrance estimates have fallen over time as more disease-free asymptomatic carriers are identified. Table 2 shows the changes in estimates in age-related penetrance, for all SDHB carriers (Table 2a) and then specifically for asymptomatic carriers only (Table 2b). More recent studies suggest figures as low as 22-26% at age 60 years  ADDIN EN.CITE (32, 33) and 30-44% at age 80 years  ADDIN EN.CITE (33, 35) and some authors suggest as little as 1-3% at <20 years  ADDIN EN.CITE (29, 32, 35) in the asymptomatic carrier population, with recent suggested significant differences in prevalence between male and female carriers  ADDIN EN.CITE (32) . The most recent analysis  ADDIN EN.CITE (33) is based only on clinically apparent disease at the time of genetic testing, so these figures will underestimate the true penetrance, as they do not factor in asymptomatic disease.

Phenotype
 A recent review (36) concluded that, although the most common site of paraganglioma (PGL) disease in SDHB mutation carriers is intra-abdominal/extra-adrenal, it also highlighted that a significant number of patients present with a phaeochromocytoma (PCC) (20-25%) and/or a head and neck PGL (HNPGL) (20-30%). The majority of studies combine all PGLs that occur in sympathetic locations. Where data are available in the literature  ADDIN EN.CITE (23-31, 37-42) we have calculated the breakdown of PPGLs that occur by specific tumour locations (Figure 1 and supplementary table 2). We provide two sets of data for patients that develop a tumour (supplementary table 2); firstly, the percentage chance of this being at any given site (figure 1a). In combination with prevalence data, this enables one to define the clinical risk to the patient. Secondly, the percentage of tumours that occur at each site, to help define which sites warrant surveillance imaging. 

Interestingly, although it is widely recognized that the most likely site to develop a PGL is extra-adrenal abdominal, the combined data suggest the risk of developing HNPGL is just as high. The risk of developing a PCC appears to be quite low and the risk of bilateral PCC in SDHB carriers is extremely rare. These figures are not dissimilar to a previous review showing, for patients that had developed a tumour only 12% had a PCC (43). The large cohort of SDHB patients with tumours reported in the PGL.EVA study also had a high rate of HNPGL (>50%)  ADDIN EN.CITE (23). It is possible that the combined data above are skewed by the inclusion of cohorts containing a large number of Dutch founder mutations, with an apparent predominance of HNPGLs. If the three large Dutch studies are removed  ADDIN EN.CITE (29, 31, 41) 18.75% of patients presented with PCC, 37.5% with at least one extra-adrenal abdominal PGL, 20.4% with at least one HNPGL, 10.8% with a thorax PGL, with similar figures for pelvic and bladder PGLs. 

For a smaller cohort of combined studies  ADDIN EN.CITE (24-27, 30, 31, 37, 40, 41) totalling 191 PPGLs, we have calculated the median age at diagnosis for each site. This did not differ significantly for PPGLs occurring at adrenal, extra-adrenal abdominal, thorax, bladder or pelvic sites (median ages at diagnosis 32, 30.5, 33, 27, 29.5 years respectively), but median age of diagnosis was older for those with HNPGLs at 42.5 years (range 21-93 years). This may be influenced by HNPGLs being generally silent tumours and therefore being detected later. The oldest patient identified was 93 years with a HNPGL identified on surveillance imaging (30). Although the prevalence is much lower, PPGLs occur in the paediatric population, and there are some data to suggest that they are much more likely to become malignant, with figures reported as high as 85%  ADDIN EN.CITE (39). This is especially important when considering at which age to begin surveillance. Table 3 shows the youngest patient identified with disease for the different SDH subunits divided by location of tumour.

Recent attempts have been made to define a genotype-phenotype correlation in SDHB mutation carriers. Ricketts et al  ADDIN EN.CITE (44) compared mutations predicted to cause absent or unstable protein with missense mutations that cause no loss of protein stability. Although more recently these same authors  ADDIN EN.CITE (33) have extended their cohort and report no difference in age related risks of PPGL between missense and truncating mutations, they did suggest a non-significant trend towards higher overall penetrance in mutation carriers with the mutation predicted to cause the most severe protein instability (p.Ile127Ser). They suggested that there was a higher risk of HNPGL specifically with the p.Gly96Ser missense mutation (causing abnormal splicing) and that there was a non-significant trend towards an increased risk of malignancy at age 60 years when mutations occurred in the first 300 nucleotides than with more 3’ mutations. Recently Jochmanova et al  ADDIN EN.CITE (32) have suggested that there is a difference in age-related penetrance between genders, with a penetrance of 71.8% at age 75 years in males compared to 30.8% in females. They further analysed the most common six specific mutations (of the 48 identified) in their cohort and suggested a possible (but not statistically significant) slower rate of disease in 4 mutations (Ile127Ser, IVS1+G>T, exon 1 deletion, Arg90X) when compared to patients harbouring mutations Val140Phe and Arg46X. Further definition of any genotype/phenotype correlations, if present, will clearly enable adaptation of screening programmes.

Malignant risk
SDHB mutation carriers have the highest rate of malignant transformation at approximately 30%  ADDIN EN.CITE (38, 45). It has been postulated that this may be due to the higher incidence of disease at extra-adrenal sympathetic sites  ADDIN EN.CITE (13, 45-47).  A detailed systemic review and meta-analysis has been recently undertaken (48) and included 9 cohorts of SDHB mutation carriers with malignant disease. The pooled risk for incidence of malignancy was 17% for all SDHB mutations carriers (including both index cases and asymptomatic carriers).

Where detailed clinical information was available  ADDIN EN.CITE (24-27, 31, 38, 39, 41, 49) we have calculated malignancy risk by tumour location. This included a total of 344 tumours, where 95 cases were associated with malignancy (27.6%), in keeping with previous reports. Probably of more clinical relevance is to look at the malignancy risk as a percentage of the total tumours that occurred at each site (Figure 2a and supplementary table 2). These data actually suggest that the risk of malignant transformation is the same for both PCC and extra-adrenal abdominal PGLs in SDHB carriers. The notable exception here is bladder PGLs; although the series was small, concern has been raised about their substantial malignant potential  ADDIN EN.CITE (50, 51). Another key finding is that the risk of malignant transformation of HNPGL in SDHB carriers appears to be lower compared to PPGLs that develop at other sites. Clearly these data should be interpreted with caution as the numbers of tumours at some sites are small.

Other associated tumours
Other non-chromaffin tumours have been associated with SDHB mutations. Approximately 50-60 SDHB-related renal tumours (RCC) have been reported  ADDIN EN.CITE (24, 26, 28, 32-34, 41, 52-55). SDHB-related RCC appear to have a more aggressive behaviour than their sporadic counterparts and occur at younger ages  ADDIN EN.CITE (52, 56) with bilateral disease occurring in 30% of SDHB-deficient cases and metastatic disease occurring in 33% of RCC cases (36). SDH-related RCCs have distinct clear cell pathological features and are now recognized as a unique subtype of RCC  ADDIN EN.CITE (54, 57-59). It has been hypothesised that there may be certain mutations that increase the risk of developing a renal tumour; those with Arginine substitutes appear particularly predisposed  ADDIN EN.CITE (53, 60), although other genotype associations have also been reported  ADDIN EN.CITE (55, 61). Gastrointestinal stromal tumours (GIST) are reported to occur in approximately 2% of SDHB carriers (36) and are predominantly gastric in origin. A predisposition to developing pituitary adenomas has also been suggested in the presence of SDHB mutations and have also been shown to have a specific histological phenotype with large vacuoles  ADDIN EN.CITE (62). Pituitary adenomas have been reported in nine cases of patients carrying SDHB mutations, six of which also had PPGL  ADDIN EN.CITE (63). Only three of these, however, had proven loss of heterozygosity (LoH) with intracytoplasmic granules and abnormal SDHB expression, thus confirming the SDHB mutation involvement  ADDIN EN.CITE (62). 

SDHD

Penetrance
Mutations in the SDHD gene account for approximately 5-9% of cases of all PPGLs  ADDIN EN.CITE (8, 20), and are affected by maternal imprinting, with disease only penetrant if the abnormal gene is inherited from the paternal line. A recent review  ADDIN EN.CITE (64) highlighted that mutations in SDHD are currently the leading cause of hereditary HNPGLs (50%). To date, a total of 160 unique mutation variants have been reported in the SDH database (22). 

The predominant clinical feature of SDHD mutation carriers is the development of HNPGL, with 85% of carriers developing tumours at these sites (36).  PCC and extra-adrenal sympathetic PGLs are reported to occur less frequently in 10-25% and 20-25% of carriers respectively  ADDIN EN.CITE (27). Multifocal disease is much more common in SDHD carriers, with estimates that 55-60% of carriers develop multiple tumours  ADDIN EN.CITE (27). 

The importance of surveillance screening in asymptomatic relatives is again highlighted when analysing studies that separate out the asymptomatic carriers/relatives from the index cases (Table 1). These combined cohorts provide data on 257 asymptomatic SDHD carriers and demonstrate a tumour detection rate of 52.9%  ADDIN EN.CITE (23, 25-27, 33, 34, 65-69).

Phenotype
We have used published clinical data to calculate the risk of tumour formation based on disease site (Figure 1b and supplementary table 3)  ADDIN EN.CITE (3, 15, 23, 25-27, 37, 40, 65-68, 70-75). We again provide two sets of data for patients that develop a tumour (supplementary table 3); firstly, the percentage chance of this being at any given site (figure 1b). In combination with prevalence data, this enables one to define the clinical risk to the patient. Secondly, the percentage of tumours that occur at each site, to help define which sites warrant surveillance imaging. This data confirms that the most common site of disease in SDHD carriers is in the head and neck, where multiple PGLs can occur, as previously reported. It does highlight that there is a high risk of patients developing a PCC (35.8%) or abdominal PGL (9.4%) and a small, but significant risk of developing PGLs at other sympathetic sites, so any surveillance screening should include these sites and not be exclusive to the head and neck. 

Some studies have attempted to elucidate phenotypes related to specific mutations. Ricketts et al  ADDIN EN.CITE (44) demonstrated mutations that affected protein stability were associated with earlier age of onset and a higher risk of developing PCC. Additionally Heesterman et al (67) found that individuals with p.Leu139Pro mutations had a higher penetrance and higher risk of multiple tumours (when compared to the most common mutation in this cohort, p.Asp92Tyr). A recent paper  ADDIN EN.CITE (33) confirmed the specific SDHD missense mutation p.Pro81Leu had a low risk of sympathetic PGL, although similar risk to other mutations of HNPGL (1 PPGL and 37 HNPGL in cohort of 53 carriers) and of note, two of these individuals with HNPGL developed metastases. This mutation is predicted in silico to have only mild effect on protein stability and the authors suggest this may mean that the tumorigenesis process may be different between sympathetic and parasympathetic tumours. A study following the natural growth rate of 28 SDHD-associated HNPGL radiologically, demonstrated growth in only five tumours (17.9%) during follow up for 3.2 years (+/-2.5years) (67). 

Malignancy risks

It is recognised that PPGLs occurring in SDHD carriers run a more benign course. A detailed systemic review and meta-analysis has been previously undertaken (48) and included 10 cohorts of SDHD mutation carriers with malignant disease. The pooled risk for incidence of malignancy was 8% for all SDHD mutations carriers. Malignancy has been reported across a spectrum of SDHD mutations (76). 

Where clinical data was available  ADDIN EN.CITE (15, 26, 27, 33, 39, 40, 65, 68, 73, 75, 77) we have calculated malignancy risk by tumour location (Figure 2b and supplementary table 3). This included a total of 413 tumours, where 28 cases were associated with malignancy (6.7%). Although still relatively low at < 10%, the risk of malignant transformation was highest in HNPGLs (7.5%), and similar for all the sympathetic sites (3.8-5.2%). 

Other associated tumours
RCC, GIST and pituitary adenoma have also been associated with SDHD mutations  ADDIN EN.CITE (44, 63). Very few RCC have been reported in patients with SDHD mutations and lifetime risk is extremely low (<1%)  ADDIN EN.CITE (33, 52, 55, 61). Five cases of patients carrying SDHD mutations have been reported with pituitary adenomas and PPGL  ADDIN EN.CITE (63). Only two of these however have proven LoH and negative SDHB immunostaining, and both were macroprolactinomas  ADDIN EN.CITE (78, 79).

SDHC

Penetrance
Mutations in SDHC gene account for 1-2% of cases of all PPGLs  ADDIN EN.CITE (8, 20). To date, a total of 83 unique mutation variants have been reported in the SDH database (22). Andrews et al  ADDIN EN.CITE (33) estimated risk of disease at age 60 years at 25% in mutation positive non-probands. 

Phenotype
Many fewer cases of patients with SDHC have been reported compared to SDHB and SDHD and therefore a detailed phenotype is not well described. The reports focus mainly on index cases and suggest a predominance of HNPGLs with a few sympathetic PGLs reported. Where clinical data are available, we have combined the reported cohorts  ADDIN EN.CITE (25, 28, 33, 43, 49, 68, 73, 74, 80-86) giving a total of 172 individuals harbouring SDHC mutations, with 127 individuals developing 166 tumours (most cohorts are of index cases only). Of the 127 individuals with tumours; 69.35% had at least one HNPGL, 22% had a PCC, 11% an extra-adrenal abdominal PGL, and 4.7% a thorax PGL (table 4). 36% of patients had multiple tumours, which included either multiple HNPGLs or a HNPGL combined with a single sympathetic PGL and 5.5% developed malignant disease. For the 67 patients where age of diagnosis was available the median age was 45 years (range 12-84 years). This did not greatly differ depending on site of disease.

Other associated tumours
Two cases of pituitary adenoma occurring in individuals with SDHC mutations have been described with macroprolactinoma and HNPGL, but no tissue was available for LoH studies to prove pathogenicity  ADDIN EN.CITE (63). Eight RCC  ADDIN EN.CITE (52, 55, 87) and multiple GISTs  ADDIN EN.CITE (88-90) have been reported in patients harbouring SDHC mutations. 

SDHA

Penetrance
Mutations in the SDHA gene were first associated with autosomal recessive inheritance of the mitochondrial disease Leigh syndrome (juvenile encephalopathy)  ADDIN EN.CITE (91) and more recently with severe neurological dysfunction and cardiomyopathy  ADDIN EN.CITE (92). As an autosomal dominant inherited tumour suppressor gene, SDHA mutations were only proven to be associated with inherited familial PGL syndromes in 2010  ADDIN EN.CITE (6) and not surprisingly, there is less clinical understanding of the natural history of this subunit, with the gene being tested for less often and with numerous variants of unknown significance. Mutations in the SDHA gene account for <1% of all PPGL cases  ADDIN EN.CITE (8, 20) and only 3% of familial cases. To our knowledge no PGL familial disease has been reported in SDHA carriers and the penetrance therefore remains unknown but is likely to be very low (93).

Phenotype
Several recent case reports or small cohorts of patients carrying SDHA mutations have been published  ADDIN EN.CITE (94-101). To date the total number of cases reported is 93 with 41 different mutations. Table 4 shows the number of patients that have developed PPGLs at different sites.  Malignant disease was reported in 9.6% of patients  ADDIN EN.CITE (40, 94-96, 100, 101), although of note the metastases seem to appear late  ADDIN EN.CITE (94, 95, 102). Median age at diagnosis was 40 years (range 12-81 years). 

Other associated tumours
GIST and pituitary adenoma have been described in eight  ADDIN EN.CITE (95, 100, 101) and four patients  ADDIN EN.CITE (62, 101) respectively carrying germline SDHA mutations with PPGL disease, and metastatic GIST has been reported (95). SDH-deficient GIST are most commonly associated with germline mutations in SDHA, accounting for 30% of SDH-deficient GISTs with 20% due to SDHB, D and C germline mutations (90). Interestingly approximately 50% of SDH-deficient GIST are due to somatic mutations and SDH-deficient GIST are now recognised as a unique class of GIST  ADDIN EN.CITE (90, 103).

SDHAF2

Very few cases of PPGL associated with mutations in SDHAF2 have been described  ADDIN EN.CITE (7, 104-107). The association was first described in 2009  ADDIN EN.CITE (7) and is known to be affected by maternal imprinting, as in SDHD. Mutations in the SDHAF2 gene account for <0.1% of cases of all PPGLs (20). 

To date only 60 cases have been described including at least two different families with identical missense mutation c.232G>A p.Gly78Arg in exon 2. Forty-nine of the 57 (85.9%) individuals investigated had disease (table 4), the majority of whom had multiple HNPGLs; one patient with a thorax PGL and one with an intra-thyroidal PGL have also been reported. Additionally, a single nucleotide polymorphism of unknown pathogenicity was identified in a patient with a PCC in both the tumour and germline. No malignant disease has been reported.

A single patient has been described with SDHAF2 variant (c.-52T>C), with HNPGL and a somatotroph pituitary macroadenoma, but no tissue was available for analysis  ADDIN EN.CITE (62, 63). To our knowledge no RCC or GIST have been reported in patients with SDHAF2 mutations.


Modality and frequency of imaging SDH mutation carriers (current practice)

Very few studies separate out the different SDH subunits in terms of surveillance screening. Most centres use SDHB mutation carriers as the basis of their screening programmes, as this group make up the bulk of the affected population in the majority of centres. Table 1 in the supplementary data summarises the different suggested surveillance programmes that have been reported, and is an updated table published previously (19).

Recommendations for screening have often been based on studies looking at sensitivity and specificity of different imaging modalities in comparison to each other  ADDIN EN.CITE (23, 108-110) and some recommendations regarding specific imaging modalities and frequencies, appropriate when there was less knowledge and an assumed higher penetrance, would no longer be considered valid by the recommending centres. An understanding of the different sensitivities and specificities is important but must be interpreted in the setting of the clinical goal of surveillance in a particular cohort. The goal of a surveillance programme is to detect all tumours before they cause morbidity or undergo malignant transformation, thereby allowing therapeutic intervention at the correct time (which may be after a period of more focused surveillance). Historically surveillance recommendations have included the use of MRI or CT for surveillance screening of head and neck, chest, abdomen and pelvis. Some recommendations have included the routine or first screen use of whole body scintigraphy (MIBG or 68Ga DOTATATE), In-pentetreotide, FDG, or F-DOPA PET  ADDIN EN.CITE (11, 21, 23, 25-27, 29, 41, 42, 64, 66, 68, 69, 74, 111, 112) (see supplementary data). Since CT and MRI have similar sensitivities and specificities for the localisation of PPGLs  ADDIN EN.CITE (110, 113) and with the known evidence regarding long term risks of radiation  ADDIN EN.CITE (12, 114, 115), more centres are adopting radiation free methods for surveillance imaging in asymptomatic carriers, with MRI being the logical choice, in alignment with the Endocrine Society guidelines  ADDIN EN.CITE (11, 116). Surveillance studies using solely MRI  ADDIN EN.CITE (24, 25, 28) have demonstrated this modality to be safe and reliable in monitoring and identifying new disease in asymptomatic SDH carrier populations (although total numbers of patients remain small). The use of MRI avoids the possible risk of radiation induced tissue injury in this tumour-prone cohort. Barriers to MRI include time of scanning, cost, radiological expertise in reporting and concerns about missing lesions. Whilst radiation risks are controversial in absolute terms  ADDIN EN.CITE (117), there is a consensus that females incur greater risk than males from radiation exposure and children have about twice the risk of radiation induced cancer compared to adults in their thirties and about 5 times the risk compared to adults in their sixties for both sexes  ADDIN EN.CITE (12, 115).  Estimates suggest that the lifetime risk of radiation induced cancer in children (0-19 years) is estimated as 8-14% per Sievert (Sv) of radiation exposure and 4.22-8.54% for adults 20-49 years (12). Typically, in practical terms, this confers a lifetime radiation induced fatal cancer risk of 1:2000 for an adult and 1:1000 for a child undergoing a CT scan of the chest, abdomen and pelvis (12). This data may underestimate the risk in a tumour-prone group. One of the concerns about sole use of radiological imaging (e.g. CT/MRI) in screening is missing tumours, particularly in the thorax and some authors have suggested that nuclear imaging could be used to detect these  ADDIN EN.CITE (23), although of note the lower sensitivity in detecting PGL in the thorax with CT in this study was ameliorated by a second imaging review in expert hands. If MRI is to be adopted for surveillance a consensus needs to reached with regards to weighing the benefits and risks of different types e.g. rapid sequence vs conventional  ADDIN EN.CITE (28, 77), angio-MRI in HNPGL  ADDIN EN.CITE (118), with and without contrast  ADDIN EN.CITE (119), and the importance and use of different sequences.

Detailed reviews elsewhere discuss the advantages and disadvantages of different imaging techniques. In summary, functional imaging modalities are based on the increased glucose uptake in tumours (e.g., 18F-FDG PET) or the preferential uptake of substrates in the PPGL processing pathways (e.g., MIBG, 6-[18F]-fluorodopamine (18F-FDA), and 18F-DOPA techniques)  ADDIN EN.CITE (11, 19, 23, 67, 69, 120-125). Arguments have been made for the use of techniques reliant on tumour hypermetabolic activity, rather than PPGL specific metabolism, to increase sensitivity for less differentiated tumours (69). Functional imaging using 18F-FDG has been shown to be more sensitive in the detection of PPGLs in SDHB/D carriers compared to 123I-MIBG, and is more sensitive in the detection of SDHB/D related metastases compared to non SDH-related disease  ADDIN EN.CITE (69, 123, 124). 68Ga-Dodecanetetraacetic acid-Octreotate (DOTATATE) PET/CT has been shown to be superior in the localization of SDHB-associated metastatic PPGLs  ADDIN EN.CITE (125) and HNPGLs  ADDIN EN.CITE (126, 127). A retrospective sub-analysis of the PGL.EVA cohort evaluated the use of a rapid contrast-enhanced angio-MRI, which has a much shorter duration of scanning of 5 to 10 minutes, in detecting HNPGL in SDHx mutation carriers and found no difference in performance with standardized MRI  ADDIN EN.CITE (118). The most sensitive method in the evaluation of non–head and neck primary PPGLs is suggested to be 18F-fluorodopamine PET, but availability is limited  ADDIN EN.CITE (11). Both MIBG  ADDIN EN.CITE (23, 67, 128) and 111In-diethylene triamine pentacetic acid-pentetreotide scintigraphy (octreoscan)  ADDIN EN.CITE (11) have been shown to be less useful in SDHx surveillance imaging.

 The Endocrine Society clinical practice guidelines, however, suggest that CT and nuclear medicine imaging modalities should be reserved for further characterization of detected tumours to avoid ionizing radiation exposure especially as this cohort of patients require recurrent scanning, often from a young age and, by definition, are a group prone to tumour development.
Regular clinical review and biochemical assessment (plasma or 24 hour urine metanephrines) of SDH mutation carriers is universally recommended. However, it is also recognised that with a sensitive imaging surveillance programme, all lesions could be detected before they have a clinical or biochemical correlate. Suggested frequency of imaging surveillance is again highly variable (supplementary table 1). Recommendations have not usually been sub-type specific and range from 1-5 year intervals. With the recognition of the lower penetrance of disease and a better understanding of natural history of disease (e.g. slow growth of HNPGL) these intervals can probably start to be extended, following a baseline negative first screen. An increased understanding of the differences in phenotypes between subunits is likely, in turn, to facilitate individualised surveillance imaging protocols, focusing on the most likely site of disease. 

Conclusion

The overarching aim of any SDH surveillance programme must be to identify disease at an early stage with small tumour sizes in order to allow intervention at the appropriate time, improve cure rates and limit the chance of malignant transformation. In our opinion, there are now sufficient published clinical data (particularly for SDHB and SDHD) to begin the process of drafting recommendations for surveillance screening which take into account the known epidemiology of each subunit and the goals of screening for each subunit (with future modifications as further data become available). A consensus also needs to be reached with respect to the acceptable “miss rate” and the target detection level which will guide the frequency of scanning (most nationwide screening programmes being set for a detection level of 5% (129)). For completion, in the absence of any consensus guidelines table 5 outlines a possible MRI based sub-unit specific protocol with goals of screening and the rationale behind the frequency. This is based on our review of the data, recognition of the Endocrine Society guidelines  ADDIN EN.CITE (11, 116) which recommend MRI should be used in patients in whom radiation exposure should be limited (e.g. patients with known germline mutations), and our personal experience with MRI in this cohort of patients. We will implement these at our centre until consensus guidelines are published. The subjective nature of these is fully acknowledged. Like many areas of clinical practice, the modality and frequency of screening that individual centres adopt will be dependent on issues such as cost and local expertise. It would be valuable for any surveillance programmes to undergo prospective auditing and validation so that successful programmes can be more widely adopted. Biomarkers will also have an increasing importance in surveillance programmes when they become sensitive and specific enough to identify early disease. 

This study was carried out in accordance with the Declaration of Helsinki and all the applicable local regulations. As this is an analysis on subjects’ data taken during normal clinical practice, no specific authorization by ethic committee was sought. 
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